A Phase IV Open Label Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Transitioning From Previous Systemic Antipsoriasis Therapies (Methotrexate, Cyclosporine, Retinoids or PUVA, NBUVB) to Raptiva 1mg/kg/ Week Therapy.

Trial Profile

A Phase IV Open Label Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Transitioning From Previous Systemic Antipsoriasis Therapies (Methotrexate, Cyclosporine, Retinoids or PUVA, NBUVB) to Raptiva 1mg/kg/ Week Therapy.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2012

At a glance

  • Drugs Efalizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2012 Additional trial location (Netherlands) added as reported by European Clinical Trials Database.
    • 09 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top